MX2009006177A - Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida. - Google Patents

Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida.

Info

Publication number
MX2009006177A
MX2009006177A MX2009006177A MX2009006177A MX2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A
Authority
MX
Mexico
Prior art keywords
side effects
effects including
including reduced
acetaminophen
minimized side
Prior art date
Application number
MX2009006177A
Other languages
English (en)
Spanish (es)
Inventor
Eric M Soderling
Original Assignee
Eric M Soderling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eric M Soderling filed Critical Eric M Soderling
Publication of MX2009006177A publication Critical patent/MX2009006177A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009006177A 2006-12-09 2007-12-08 Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida. MX2009006177A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87374306P 2006-12-09 2006-12-09
US11/952,556 US20080139654A1 (en) 2006-12-09 2007-12-07 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
PCT/US2007/025167 WO2008073344A1 (en) 2006-12-09 2007-12-08 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Publications (1)

Publication Number Publication Date
MX2009006177A true MX2009006177A (es) 2009-08-31

Family

ID=39498949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006177A MX2009006177A (es) 2006-12-09 2007-12-08 Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida.

Country Status (13)

Country Link
US (1) US20080139654A1 (enExample)
EP (1) EP2094253A4 (enExample)
JP (1) JP2010513229A (enExample)
KR (1) KR20090089867A (enExample)
CN (1) CN101588797A (enExample)
AU (1) AU2007332812A1 (enExample)
BR (1) BRPI0721216A2 (enExample)
CA (1) CA2671490A1 (enExample)
EA (1) EA200970449A1 (enExample)
IL (1) IL199056A0 (enExample)
MX (1) MX2009006177A (enExample)
WO (1) WO2008073344A1 (enExample)
ZA (1) ZA200904764B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080187A1 (it) * 2008-02-07 2009-08-08 Velleja Res Srl Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
US20110014285A1 (en) * 2009-07-15 2011-01-20 Herzenberg Leonore A N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
TR201007652A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Sinerjik etki.
WO2013044085A1 (en) * 2011-09-23 2013-03-28 Subramanian Veerappan Sellappan A solid, edible, chewable laxative composition
WO2014159994A1 (en) * 2013-03-13 2014-10-02 Nbip, Llc Compositions and methods for removing the odor from glutathione when mixed in an aqueous system
US10104882B2 (en) * 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
AU2017208123B2 (en) * 2016-01-11 2022-04-21 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
KR101962518B1 (ko) 2016-09-13 2019-03-26 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물
WO2018089400A1 (en) * 2016-11-09 2018-05-17 The Feinstein Institute For Medical Research Iguratimod as an mif inhibitor
KR102813413B1 (ko) 2019-08-27 2025-05-27 주식회사 엘지에너지솔루션 단위셀의 두께측정장치 및 두께측정방법
US11590090B2 (en) * 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GR1002731B (el) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Also Published As

Publication number Publication date
KR20090089867A (ko) 2009-08-24
ZA200904764B (en) 2012-12-27
CN101588797A (zh) 2009-11-25
JP2010513229A (ja) 2010-04-30
EA200970449A1 (ru) 2009-08-28
EP2094253A4 (en) 2010-02-10
US20080139654A1 (en) 2008-06-12
AU2007332812A1 (en) 2008-06-19
CA2671490A1 (en) 2008-06-19
IL199056A0 (en) 2010-03-28
EP2094253A1 (en) 2009-09-02
BRPI0721216A2 (pt) 2014-12-02
WO2008073344A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
MX2009006177A (es) Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida.
IL185626A0 (en) Sublingual coated tablet
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
MX2008015731A (es) Tabletas sublinguales de baja dosificacion de analgesicos opiaiceos y proceso de preparacion.
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TW200716119A (en) A solid pharmaceutical dosage formulation
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
WO2007139860A3 (en) Heterobicylic metalloprotease inhibitors
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TNSN08191A1 (en) Kinase inhibitors
IL193252A0 (en) N-hydroxyacrylamide compounds
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
MX2010003591A (es) Capa protectora mecanica para formas de dosificacion solidas.
GB2456096A (en) Crystalline form of benzothiophene compound and process for preparation thereof
MX2008009830A (es) Efecto del inhibidor bst2.
MX2010006995A (es) 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico.
BRPI0509014A (pt) comprimidos desintegráveis que compreendem licarbazepina
AU2003211540A1 (en) Medicinal compositions for inhibiting tryptase
WO2008024846A3 (en) Brimonidine and timolol compositions
EA200870236A1 (ru) Моногидрат римонабанта, способ его получения и фармацевтические композиции на его основе
WO2007089657A3 (en) Crystalline forms of a farnesyl dibenzodiazepinone

Legal Events

Date Code Title Description
FA Abandonment or withdrawal